STOCK TITAN

Director at Corcept (CORT) receives 12,500 stock options vesting over one year

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics director James N. Wilson received a grant of 12,500 stock options on May 21, 2026. Each option allows him to buy Common Stock at an exercise price of $59.69 per share, expiring on May 21, 2036.

The options cover 12,500 underlying shares and were awarded as compensation, not purchased in the open market. They become exercisable in equal monthly installments over one year starting on May 21, 2026, contingent on his continued service on each monthly vesting date.

Positive

  • None.

Negative

  • None.
Insider WILSON JAMES N
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 12,500 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 12,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 12,500 options Stock Option grant to director on May 21, 2026
Exercise price $59.69 per share Exercise price of stock options
Underlying shares 12,500 shares Common Stock underlying the options
Expiration date May 21, 2036 Option expiration
Vesting period 1 year Monthly vesting from May 21, 2026 over one year
Post-transaction options 12,500 options Total derivative holdings following transaction
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 59.6900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"Exercisable ratably in equal installments on each monthly anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WILSON JAMES N

(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$59.6905/21/2026A12,500 (1)05/21/2036Common Stock12,500$0.0012,500D
Explanation of Responses:
1. Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Corcept Therapeutics (CORT) director James N. Wilson report on this Form 4?

He reported receiving a grant of 12,500 stock options for Corcept Therapeutics Common Stock. These options were awarded as compensation, not bought in the market, and give him the right to purchase shares at a fixed exercise price of $59.69 per share.

What are the key terms of the 12,500 Corcept (CORT) stock options granted to James N. Wilson?

The grant covers 12,500 stock options with an exercise price of $59.69 per share and an expiration date of May 21, 2036. The options relate to 12,500 underlying shares of Common Stock and were reported as a grant or award acquisition.

How do the Corcept (CORT) stock options granted to James N. Wilson vest?

The options vest ratably in equal installments on each monthly anniversary of May 21, 2026, over a one-year period. Vesting is conditioned on his continued service as of each monthly vesting date, meaning unvested portions depend on ongoing board service.

Did James N. Wilson buy or sell any Corcept (CORT) shares in the open market in this filing?

No open-market purchases or sales were reported. The Form 4 shows a single derivative transaction coded as a grant or award acquisition, reflecting compensation-related stock options rather than a discretionary market trade in Corcept Therapeutics Common Stock.

What is James N. Wilson’s reported option position in Corcept (CORT) after this grant?

After the reported transaction, he holds 12,500 stock options related to Corcept Common Stock. This amount matches the size of the grant, indicating the newly awarded options constitute his reported derivative position in this filing, with no additional option holdings listed.